PROVECTUS BIOPHARMACEUTICALS, INC.
PROVECTUS BIOPHARMACEUTICALS, INC. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is Indigotindisulfonate Sodium Injection, USP as an Aid in the Determination of Ureteral Patency in Pediatric Patients on December 15, 2026. There is 1 upcoming event on record.
Cash runway is approximately 9.7 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
| Date | Event | Type | Phase |
|---|---|---|---|
| December 15, 2026 | Indigotindisulfonate Sodium Injection, USP as an Aid in the Determination of Ureteral Patency in Pediatric Patients | Trial Milestone | Phase 3 |
Track PVCT alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open PVCT in the tracker| Date | Event | Type | Phase |
|---|---|---|---|
| July 1, 2026 | 8-K filed: Leadership change | Corporate | — |
| June 30, 2026 | Indigotindisulfonate Sodium as an Aid in Determination of Ureteral Patency in Patient's With Renal Impairment | Trial Milestone | Phase 4 |
| June 18, 2026 | 8-K filed: Reg FD disclosure | Filing | — |
| April 21, 2026 | 8-K filed: Other event | Filing | — |
| January 31, 2026 | Indigotindisulfonate Sodium Injection, USP as an Aid in the Determination of Ureteral Patency | Trial Milestone | Phase 4 |
| June 18, 2025 | 8-K filed: Reg FD disclosure | Filing | — |
| June 3, 2021 | 3,3'-Dioxo-2,2'-Bisindolylidene-5,5'-Disulfonate Disodium 0.8% Solution as an Aid for Ureteral Patency | Trial Milestone | Phase 3 |
Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.